1. Pink Sheet
  2. >>Product Reviews

Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?

 
• By Derrick Gingery

Agency is still working to get oncology center of excellence off the ground and has other large pending reorganizations that could take precedence.

Capitol House

FDA may wind up only meeting the minimum requirements for establishing intercenter institutes within the agency that are included in the new version of the 21st Century Cures bill.

The latest draft of the legislation, which is expected to receive a vote in the House of Representatives on Wednesday, includes a provision requiring the agency to create cross-center groupings to better coordinate its handling of major diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.